Advaxis (NASDAQ:ADXS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Wednesday. The firm presently has a $0.50 target price on the biotechnology company’s stock. Zacks Investment Research‘s price target points to a potential upside of 29.23% from the stock’s previous close.
According to Zacks, “Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body’s immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company’s products in development include Lovaxin C and Lovaxin B, Lovaxin P. “
ADXS has been the subject of several other research reports. HC Wainwright reissued a “hold” rating on shares of Advaxis in a research report on Wednesday, January 16th. ValuEngine cut shares of Advaxis from a “buy” rating to a “hold” rating in a research report on Friday, January 25th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $2.38.
Shares of ADXS opened at $0.39 on Wednesday. The firm has a market cap of $25.20 million, a price-to-earnings ratio of -0.30 and a beta of 3.97. Advaxis has a twelve month low of $0.18 and a twelve month high of $2.25.
Advaxis (NASDAQ:ADXS) last announced its quarterly earnings results on Thursday, January 10th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.14). The firm had revenue of $1.13 million for the quarter, compared to analysts’ expectations of $1.10 million. Advaxis had a negative net margin of 1,096.88% and a negative return on equity of 187.23%. As a group, equities research analysts expect that Advaxis will post -0.51 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the business. Virtu Financial LLC boosted its position in Advaxis by 740.4% during the 4th quarter. Virtu Financial LLC now owns 176,213 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 155,246 shares during the period. Two Sigma Investments LP boosted its position in Advaxis by 2,468.2% during the 4th quarter. Two Sigma Investments LP now owns 369,815 shares of the biotechnology company’s stock valued at $70,000 after buying an additional 355,415 shares during the period. BlackRock Inc. boosted its position in Advaxis by 3.1% during the 4th quarter. BlackRock Inc. now owns 1,446,288 shares of the biotechnology company’s stock valued at $275,000 after buying an additional 43,368 shares during the period. Renaissance Technologies LLC boosted its position in Advaxis by 173.0% during the 3rd quarter. Renaissance Technologies LLC now owns 1,191,846 shares of the biotechnology company’s stock valued at $1,120,000 after buying an additional 755,352 shares during the period. Finally, Vanguard Group Inc boosted its position in Advaxis by 48.3% during the 3rd quarter. Vanguard Group Inc now owns 2,630,658 shares of the biotechnology company’s stock valued at $2,473,000 after buying an additional 857,026 shares during the period. 22.77% of the stock is owned by institutional investors and hedge funds.
Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.
See Also: Why do companies pay special dividends?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.